Institute of Orthopedics, The Second Hospital, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Biosci Rep. 2012 Dec;32(6):511-9. doi: 10.1042/BSR20110118.
Osteoporosis is a common disease in the elderly population. The progress of this disease results in the reduction of bone mass and can increase the incidence of fractures. Drugs presently used clinically can block the aggravation of this disease. However, these drugs cannot increase the bone mass and may result in certain side effects. Statins, also known as HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors, have been widely prescribed for CVD (cardiovascular disease) for decades. Nonetheless, several studies have demonstrated that statins exert bone anabolic effect and may be helpful for the treatment of osteoporosis. Several experiments have analysed the mechanisms of bone anabolism regulated by statins. In the present paper, we review the mechanisms of promoting osteogenesis, suppressing osteoblast apoptosis and inhibiting osteoclastogenesis.
骨质疏松症是老年人群中的一种常见疾病。该疾病的进展导致骨量减少，并可增加骨折的发生率。目前临床上使用的药物可以阻止该疾病的恶化。然而，这些药物不能增加骨量，并且可能会产生某些副作用。他汀类药物，也称为 HMG-CoA（3-羟基-3-甲基戊二酰辅酶 A）还原酶抑制剂，几十年来已被广泛用于 CVD（心血管疾病）的治疗。然而，有几项研究表明，他汀类药物具有骨合成代谢作用，可能有助于骨质疏松症的治疗。一些实验分析了他汀类药物调节的骨合成代谢的机制。在本文中，我们综述了促进成骨、抑制成骨细胞凋亡和抑制破骨细胞生成的机制。
